AR-501 (Gallium Citrate): Novel anti-infective for the growing problem of antibiotic resistance
To complement our suite of targeted human monoclonal antibodies, we have developed AR-501, an inhalable, broad-spectrum, small molecule anti-infective that acts as an iron analog and works by effectively starving bacteria of iron and interfering with iron-dependent metabolic pathways required for pathogenicity.
AR-501 has broad anti-bacterial activity against Gram-negative and Gram-positive bacteria, including antibiotic-resistant strains. AR-501’s inhibitory activity reaches bacteria growing in mature biofilms and prevents biofilm formation. AR-501 is being developed for the treatment of life-threatening bacterial lung infections in patients with cystic fibrosis (CF).
It is currently in late preclinical stage development and has completed preclinical animal studies. This program is approaching IND filing, and a Phase 1/2a clinical trial of AR-501 in cystic fibrosis patients is projected to initiate in 2H 2018.
Aridis’ AR-501 is a promising therapeutic option for controlling chronic lung infections with unique benefits compared to current standard of care antibiotics:
- Broad activity against Gram-negative and Gram-positive bacteria, including difficult-to-treat P. aeruginosa and B. cepacia
- Effective against drug-resistant strains and in the presence of bacterial biofilms
- Very low to non-detectable incidence of drug resistance